Trial Profile
A comparison of MS disease activity between patients treated with natalizumab and fingolimod
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Mar 2018
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 27 Feb 2016 New trial record